Bringing the Oncology Community Together
Becoming a Champion of Change:Educating Fellows on the Costs of Cancer Care
On a recent day in hematology clinic, I stood dutifully by my attending as he sorted through bone marrow slides
Finance for Fellows
PARP Inhibitors for Breast and Ovarian Cancers
PARP inhibitors represent an exciting new class of anticancer agents and are currently being evaluating in phase III for a number of different indications.
Anderson Provides Insight Into Novel Agents in Multiple Myeloma
The treatment of patients with multiple myeloma is poised to undergo a dramatic transformation, as novel monoclonal antibodies and combination strategies race toward approval.
To Succeed, Urology Practices Must Change With the Times
Entrepreneur James Feldman, chief innovation officer of the Chicago-based company Shift Happens!, calls himself “a doctor for business.”
FDA Extends Panobinostat Review Period for Multiple Myeloma
The FDA has extended the review period for panobinostat (LBH589) in combination with bortezomib (Velcade) and dexamethasone for patients with previously treated multiple myeloma by 3 months, placing a new decision date in early 2015.
Government Come to Call? How to Protect Your Practice
Urologists hear quite a bit about risk from the legislative and regulatory angles.
Pfizer, Merck KGaA Collaboration Accelerates PD-L1 Inhibitor Development
Pfizer and Merck KGaA have agreed to collaborate on the development of the PD-L1 inhibitor MSB0010718C as a potential treatment for multiple types of cancer.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.